Eyenuk

Eyenuk, Inc. is a global leader in artificial intelligence (AI) medical technology, specializing in autonomous disease detection and AI predictive analytics for risk assessment and disease surveillance. The company's flagship product, the EyeArt AI Eye Screening System, is designed to seamlessly integrate into clinical workflows to enable automated screening for diabetic retinopathy (DR). EyeArt is the first FDA-cleared AI technology for the autonomous detection of both more than mild and vision-threatening DR. It has been extensively validated in real-world clinical environments, tested on over half a million patient visits globally with over two million images collected.

Eyenuk serves healthcare providers, clinics, and hospitals, primarily targeting the diabetic patient population. The company operates in the medical technology market, focusing on AI-driven solutions for eye care. Eyenuk's business model revolves around selling its EyeArt system to healthcare institutions, offering both one-time sales and subscription-based models for continuous updates and support. Revenue is generated through the sale of the EyeArt system, licensing fees, and ongoing service agreements.

Eyenuk's mission is to screen every eye in the world, leveraging advanced AI to improve early detection and treatment outcomes for eye diseases. The company holds US FDA clearance, CE marking in the European Union, and a Health Canada license, underscoring its commitment to regulatory compliance and patient safety.

Keywords: AI, autonomous screening, diabetic retinopathy, FDA-cleared, EyeArt, medical technology, retinal imaging, disease detection, healthcare, predictive analytics.